Are you Dr. Mobasher?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 41 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
875 Blake Wilbur Dr
# Stanford
Stanford, CA 94304Phone+1 650-723-7621Fax+1 650-723-6661
Summary
- Dr. Mehrdad Mobasher, MD is an oncologist in Stanford, California. He is currently licensed to practice medicine in California.
Education & Training
Stanford Health Care-Sponsored Stanford UniversityFellowship, Medical Oncology, 2007 - 2010
University of California (Irvine)Residency, Internal Medicine, 2004 - 2007
Tehran University of Medical Sciences School of MedicineClass of 2001
Certifications & Licensure
CA State Medical License 2006 - 2026
Clinical Trials
- A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma Start of enrollment: 2019 May 03
Publications & Presentations
PubMed
- 52 citationsPrognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, po...Jacob D. Soumerai, Ai Ni, Mohamed Darif, Anil Londhe, Guan Xing
The Lancet. Haematology. 2019-07-01 - 55 citationsPhase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia.Ian W. Flinn, John G. Gribben, Martin J. S. Dyer, William G. Wierda, Michael B. Maris
Blood. 2019-06-27 - 96 citationsVenetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial.Andrew D. Zelenetz, Gilles Salles, Kylie D. Mason, Carla Casulo, Steven Le Gouill
Blood. 2019-05-02
Press Mentions
BeiGene Advances Leadership in CLL at ASH 2024 with New Data from Its Hematology Franchise Including BRUKINSA® and Novel Pipeline AssetsDecember 9th, 2024- BeiGene and CLL Society Partner to Advance Test Before Treat™ Campaign, Promoting Biomarker Testing to Improve Patient Outcomes in CLLDecember 4th, 2024
- BeiGene and CLL Society Partner to Advance Test Before Treat™ Campaign, Promoting Biomarker Testing to Improve Patient Outcomes in CLLDecember 4th, 2024
- Join now to see all
